Participants will also complete a brief symptom inventory at their bias retraining sessions so that we can track their progress over the course of treatment. The participant's primary therapist will also be asked to make brief ratings regarding the participant's engagement and progress at the end of active treatment. Finally, to provide an objective measure of treatment adherence, participants will be drug tested. Drug testing is conducted randomly as part of UMATS treatment, and we will request access to the results of those tests. To augment this testing, we will also conduct drug testing as part of the study to ensure that each participant has at least 4 drug tests between entry into treatment and the second neurophysiological assessment.